Drug Profile
PTG 200
Alternative Names: JNJ 67864238; JNJ-4238; PTG-200Latest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Protagonist Therapeutics
- Developer Janssen Biotech; Protagonist Therapeutics
- Class Anti-inflammatories; Peptides
- Mechanism of Action Interleukin-23 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 31 Dec 2021 Discontinued - Phase-I for Crohn's disease (In volunteers) in Australia in Q4 2021 (PO)
- 31 Dec 2021 Discontinued - Phase-II for Crohn's disease in USA, Argentina, Germany, Ukraine, Italy, Poland, Russia in Q4 2021 (PO)
- 14 Dec 2021 Janssen Research & Development terminates the phase II PRISM trial in Crohn's disease in USA, Argentina, Germany, Ukraine, Italy, Poland, Russia(PO) as IAC futility criteria were met (NCT04102111)